Tegaserod Clinical Program in Constipation-Predominant IBS

Study Dose, mg/d* N Location (% of patients)

Phase II dose-ranging

B251 1-24 547 US (54%), Europe (43%), Canada

Phase III efficacy/safety

B351 4, 12 799 US (97%), Canada

B301 4, 12 881 Europe (90%), US,  S Africa

B307 4, 4-12 845 US (66%), Europe (32%), Canada

Long-term safety

B209 4-12 579 Europe (50%), US (41%), Canada

1

*Divided into 2 daily doses.

Previous slide

Next slide

Back to first slide

View graphic version